Skip to content

Above 180/120? See warning signs

SevereHypertension

Meta-Analysis: Treating Hypertension Carries ‘Modest’ Cognitive Benefit

Severe Hypertension NetworkPublished May 21, 20203 min read
Meta-Analysis: Treating Hypertension Carries 'Modest' Cognitive Benefit

Key points

  • Antihypertensive use was associated with significantly better cognitive outcomes in a meta-analysis of randomized data.
  • “Although the lower risk associated with BP [blood pressure] treatment is modest for an individual, the effect at a population level, given the incidence of dementia in an aging population, may be considerable,” according to Michelle Canavan, PhD, of Galway University Hospital, Ireland, and colleagues.
  • “Rates of BP control are low, even in high-income countries, but especially in middle- and low-income countries, which carry the largest burden of dementia,” the authors noted.
  • BP interventions tested in the trials included in the meta-analysis were angiotensin II receptor blockers, ACE inhibitors, diuretics, beta-blockers, and calcium channel blockers, as well as comparisons of higher versus lower systolic BP targets.

Antihypertensive use was associated with significantly better cognitive outcomes in a meta-analysis of randomized data.

From 14 randomized trials published from 1994 to 2019 with a total 96,158 participants, a mean 4.1 years of blood pressure-lowering drug use compared with controls yielded:

  • Reduced incident dementia or cognitive impairment: 7.0% vs 7.5% (OR 0.93, 95% CI 0.88-0.98)
  • Less cognitive decline: 20.2% vs 21.1% (OR 0.93, 95% CI 0.88-0.99)
  • No significant change in scores on the Mini-Mental State Examination, Trail Making Test, or Cognitive Abilities Screening Instrument

Antihypertensive use was associated with significantly better cognitive outcomes in a meta-analysis of randomized data.

From 14 randomized trials published from 1994 to 2019 with a total 96,158 participants, a mean 4.1 years of blood pressure-lowering drug use compared with controls yielded:

  • Reduced incident dementia or cognitive impairment: 7.0% vs 7.5% (OR 0.93, 95% CI 0.88-0.98)
  • Less cognitive decline: 20.2% vs 21.1% (OR 0.93, 95% CI 0.88-0.99)
  • No significant change in scores on the Mini-Mental State Examination, Trail Making Test, or Cognitive Abilities Screening Instrument

“Although the lower risk associated with BP [blood pressure] treatment is modest for an individual, the effect at a population level, given the incidence of dementia in an aging population, may be considerable,” according to Michelle Canavan, PhD, of Galway University Hospital, Ireland, and colleagues. Their report was published online in JAMA.
“Rates of BP control are low, even in high-income countries, but especially in middle- and low-income countries, which carry the largest burden of dementia,” the authors noted.

BP interventions tested in the trials included in the meta-analysis were angiotensin II receptor blockers, ACE inhibitors, diuretics, beta-blockers, and calcium channel blockers, as well as comparisons of higher versus lower systolic BP targets.

The association between BP lowering and reduced dementia or cognitive impairment appeared to be driven mostly by the Syst-Eur trial from 2002, which had patients randomized to BP meds or placebo.

Of the trials included in the report, 12 reported the incidence of dementia or a composite of dementia or cognitive impairment. The other two were analyzed for the secondary outcome of change in cognitive score.

Study participants averaged 69 years of age, and 42.2% were women. Mean baseline BP was 154/83.3 mm Hg.

That the upper bound of the CI was close to 1.0 for the cognitive findings “should prompt some caution in interpreting the findings as definitive evidence of an association of BP lowering with dementia or cognitive impairment,” Canavan’s group wrote.

The meta-analysis had several limitations, including heterogeneity in trial design (e.g., controls were placebo, alternative antihypertensive agents, or higher BP targets).

“None of the included clinical trials reported dementia as their primary outcome measure in the original trial. When dementia was reported, it was as a secondary outcome with differences in outcome definition,” the investigators noted.

Additionally, dementia may have been under-detected due to preferential loss to follow-up of participants with dementia and the potential effect of survival bias, they said.

###

Nicole Lou
Nicole Lou is a reporter for MedPage Today, where she covers cardiology news and other developments in medicine

The content on this site is for information only and is not a substitute for professional medical advice, diagnosis or treatment. A reading above 180/120 with chest pain, shortness of breath, weakness or vision changes is an emergency: call 911 or your local emergency number.

Hypertensive crisis

Above 180/120? Know when it’s an emergency.

Wait five minutes and measure again. If your reading is still this high and you have any of these symptoms, call 911 or your local emergency number. Don’t wait to see if it comes down on its own.

  • Chest pain
  • Shortness of breath
  • Back pain
  • Numbness or weakness
  • Change in vision
  • Difficulty speaking

No symptoms but still above 180/120 after a second reading? Contact your doctor straight away. Outside the US, call your local emergency number.